Best GLP-1 for Weight Loss 2026: The Class Ranked
One class, six contenders, and a 17-point gap between the strongest and the most convenient — ranked by the data, not the hype.
Abstract: This is the GLP-1 weight-loss class ranked for 2026 by mean body-weight reduction in trials — semaglutide, tirzepatide, retatrutide, CagriSema, oral semaglutide and orforglipron. It explains why the order is what it is, why you cannot read the ranking table at face value, and how to choose by the metric that matters to you.
The best GLP-1 for weight loss in 2026 is not a single answer — it is a ranking, and which end of it you want depends on whether you care most about raw efficacy, regulatory approval, proven long-term outcomes, or the simple ability to take a pill instead of an injection. The class has grown from one approved drug to a tiered ladder: monotherapy GLP-1s, dual and triple agonists that stack receptors for more weight loss, an amylin combination, and — new in 2026 — oral options including the first non-peptide pill. This guide ranks them all by the trial data and then tells you how to read that ranking honestly.
This is an educational, research-focused breakdown, not medical advice. Several compounds below (semaglutide, tirzepatide, retatrutide, cagrilintide) are sold on this site for laboratory research use only; orforglipron is a prescription pharmaceutical included here only for comparison.
The best GLP-1 for weight loss in 2026, ranked
Here is the class ordered by approximate mean body-weight loss at the top studied dose in its pivotal obesity trial. Read the next section before you take this order literally — these numbers come from different trials, in different populations, measured different ways.
| Rank | Compound | Receptor target | Mean weight loss (trial) | Form | Approval status (2026) |
|---|---|---|---|---|---|
| 1 | Retatrutide | GLP-1 + GIP + glucagon (triple) | up to ~28.3% (TRIUMPH-1, 12 mg, 80 wk) | Weekly injection | Investigational — not approved |
| 2 | Tirzepatide | GLP-1 + GIP (dual) | ~22.5% (SURMOUNT-1, 15 mg, 72 wk) | Weekly injection | Approved (Zepbound) |
| 3 | CagriSema | GLP-1 + amylin | ~20.4% (REDEFINE-1, 68 wk) | Weekly injection | Under regulatory review |
| 4 | Oral semaglutide (high dose) | GLP-1 (mono) | ~15.1% (OASIS-1, 50 mg, 68 wk) | Daily pill (peptide + SNAC) | Approved for diabetes; obesity dose filed |
| 5 | Semaglutide (injectable) | GLP-1 (mono) | ~14.9% (STEP-1, 2.4 mg, 68 wk) | Weekly injection | Approved (Wegovy) |
| 6 | Orforglipron (Foundayo) | GLP-1 (mono, non-peptide) | ~11.2% (ATTAIN-1, 36 mg, 72 wk) | Daily pill | Approved for obesity (Apr 2026) |
Note that injectable semaglutide ranks below its own high-dose oral version here only because STEP-1 used the 2.4 mg dose; at the newer 7.2 mg subcutaneous dose, semaglutide reaches roughly 18.7%. The “best” answer is genuinely dose- and goal-dependent.
Why you can’t just read the table
The single most important thing to understand about every “best GLP-1” ranking online — including this one — is that you cannot directly compare percentages across separate trials. Doing so is the number-one error in the competing write-ups, and it quietly overstates some drugs and understates others.
Three reasons the columns aren’t apples-to-apples:
Different populations. STEP-1 (semaglutide) and SURMOUNT-1 (tirzepatide) enrolled adults with obesity without diabetes. People with type 2 diabetes consistently lose less weight on the same drug, so a diabetes-population number looks worse for reasons that have nothing to do with the molecule.
Different estimands. Trials report results two ways. The treatment-regimen (or treatment-policy) estimand counts everyone as randomized, including people who stopped the drug — it answers “what happens in the real world.” The efficacy (or trial-product) estimand measures the effect in people who actually stayed on treatment — a larger, more flattering number. Retatrutide’s TRIUMPH-1, for example, reads as up to 28.3% on the treatment-regimen estimand but ~30.3% on the efficacy estimand. CagriSema’s REDEFINE-1 is ~20.4% treatment-policy but ~22.7% trial-product. Compare a flattering estimand from one drug against a conservative one from another and the ranking flips.
Only head-to-head trials settle it. When two drugs are tested in the same trial, the comparison is real. So far the class has one major head-to-head obesity readout — SURMOUNT-5, which pitted tirzepatide against semaglutide directly: 20.2% vs 13.7% at 72 weeks, with 19.7% of the tirzepatide group losing ≥30% of body weight versus 6.9% on semaglutide. That is a clean win for the dual agonist. Everything else in the table is a cross-trial inference, not a measured contest.
For the deeper mechanism behind why stacking receptors moves the ceiling at all, see how GLP-1 works for weight loss.
Retatrutide — the efficacy ceiling (still investigational)
Retatrutide is the most powerful weight-loss agent yet reported, and also the only one in the top three that you cannot get by prescription. It is a triple agonist — GLP-1 plus GIP plus glucagon — and the glucagon arm is what separates it from everything below it. Where GLP-1 and GIP mainly suppress appetite (you eat less), glucagon-receptor activation adds energy expenditure and hepatic fat oxidation (you burn more and clear liver fat). Appetite-down and expenditure-up is a different metabolic equation than appetite-down alone.
The Phase 2 trial (Jastreboff 2023) showed ~24% at 48 weeks. The Phase 3 program confirmed and extended it: TRIUMPH-1 reported up to 28.3% mean weight loss at 12 mg over 80 weeks, with 45.3% of patients on the top dose losing at least 30% of their body weight — a threshold historically associated with bariatric surgery. The companion TRIUMPH-4 added a striking ~75.8% reduction in osteoarthritis knee pain and ~20% LDL drop.
The honest caveat: this is Phase 3 topline data, and retatrutide is not FDA-approved. The diabetes (TRIUMPH-2) and established-cardiovascular-disease (TRIUMPH-3) readouts are still pending in 2026, so its outcome profile in harder populations is unknown. Full detail is in the retatrutide Phase 3 TRIUMPH-1 breakdown.
Tirzepatide — the strongest approved option
If you restrict the ranking to drugs you can actually obtain and that have years of clinical use behind them, tirzepatide is the winner. The dual GIP/GLP-1 agonist delivered 22.5% at 15 mg in SURMOUNT-1, and — critically — it is the only one of the high-efficacy agents with a won head-to-head: SURMOUNT-5 beat semaglutide outright. It is FDA-approved for both obesity (Zepbound) and diabetes (Mounjaro), giving it a real-world track record that the investigational triple agonist lacks.
Tirzepatide is the practical “ceiling you can reach today.” The full dual-vs-triple trade-off — efficacy, tolerability, liver-fat and lean-mass nuances — is covered in the retatrutide vs tirzepatide comparison.
Semaglutide — the proven-outcomes benchmark
Semaglutide is the most-studied and most-prescribed GLP-1, and ranking it on weight loss alone undersells it. At 2.4 mg it produced 14.9% in STEP-1; the newer 7.2 mg subcutaneous dose pushes that toward ~18.7%. But its real differentiator is outcome data nothing else can match yet: dedicated trials show injectable semaglutide reduces major cardiovascular events, slows chronic kidney disease, and cuts heart-failure hospitalizations.
That distinction matters for ranking. Approved-and-effective is not the same as approved-and-outcome-proven. Retatrutide and tirzepatide lose more weight, but semaglutide has the deepest evidence that the weight loss translates into fewer downstream events. The class’s broader longevity and oncology signals — and their limits — are summarized in what the 2026 data shows on GLP-1 and cancer risk.
CagriSema and the amylin tier
CagriSema is the one combination in the top group that doesn’t add a third incretin — instead it pairs semaglutide with cagrilintide, a long-acting amylin analog. Amylin is a separate satiety hormone, so the combination attacks appetite through two distinct pathways. In REDEFINE-1, CagriSema produced ~20.4% weight loss (treatment-policy) / ~22.7% (trial-product) at 68 weeks, with 40% of completers losing ≥25%.
It slots in just below tirzepatide on magnitude, but it is under regulatory review rather than approved, and its headline number is estimand-sensitive (the gap between 20.4% and 22.7% is exactly the estimand issue described above). It’s the strongest evidence that amylin is the next worthwhile receptor to stack — and the reason cagrilintide-based combinations are worth watching.
The oral tier: convenience over magnitude
The newest part of the class isn’t about more weight loss — it’s about removing the needle. Two oral options now exist, and they are not equivalent.
Oral semaglutide (high dose) is the peptide you already know in pill form. Because a peptide is normally destroyed in the gut, the tablet is paired with the absorption enhancer SNAC and must be taken on an empty stomach with minimal water and no food afterward. Even then, oral bioavailability is only ~1–2% and varies wildly day to day. At the 50 mg obesity dose (OASIS-1) it reaches ~15.1% — competitive with injectable semaglutide — but the strict ritual drives high discontinuation.
Orforglipron (Foundayo) is the genuinely new thing: the first oral non-peptide GLP-1, FDA-approved for obesity in April 2026. As a small molecule it survives digestion on its own (~79% bioavailability) and can be taken any time, with or without food. The trade-off is magnitude — ATTAIN-1 showed ~11.2%, the lowest in this ranking — plus a small-molecule risk profile (hepatic CYP3A4 metabolism, a slightly larger heart-rate bump) and no long-term outcome data yet. Its edge is access, not power. The full picture is in the orforglipron (Foundayo) breakdown.
How to actually choose
“Best” only has meaning once you pick the metric. Map your priority to the ranking:
- Maximum weight loss, willing to use investigational compounds: retatrutide sits alone at the top (~28%), but it’s not approved and its hard-outcome data isn’t in.
- Maximum weight loss you can get approved, today: tirzepatide — the highest-efficacy agent with an approval and a head-to-head win.
- Proven long-term outcomes (heart, kidney): injectable semaglutide, by a wide margin.
- A pill, and you’ll actually stick to it: orforglipron for anytime convenience, or high-dose oral semaglutide if you can keep the fasted ritual.
- Two-pathway appetite control without a third incretin: CagriSema, once it clears review.
Whichever you choose, one rule is universal across the class: appetite suppression this strong puts lean mass at risk. Rapid loss without adequate protein and resistance training costs muscle, so muscle-preservation is non-negotiable on any of these — see how to keep muscle on a GLP-1. And in research contexts, the dosing principle is always start low, titrate slow: every agent here is dose-titrated specifically to limit the GI side effects that otherwise drive people off treatment.
FAQ
What is the best GLP-1 for weight loss in 2026? By raw efficacy, retatrutide (a GLP-1/GIP/glucagon triple agonist) leads at up to ~28% mean weight loss in Phase 3, but it is investigational and not approved. Among approved options, tirzepatide is the strongest at ~22.5% and is the only one with a head-to-head win over semaglutide. There is no single best — it depends on whether you weight efficacy, approval, proven outcomes, or convenience.
Is tirzepatide really better than semaglutide? In the one trial that tested them directly (SURMOUNT-5), yes: tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks. That head-to-head result is far stronger evidence than comparing their separate trials.
How does retatrutide beat tirzepatide and semaglutide? It adds a third receptor — glucagon — to the GLP-1 and GIP arms. Glucagon activation raises energy expenditure and burns liver fat on top of the appetite suppression that all GLP-1s share, which appears to lift the weight-loss ceiling.
Where do the oral pills rank? Lower on magnitude but highest on convenience. High-dose oral semaglutide reaches ~15%, but needs a strict fasted routine. Orforglipron (Foundayo), the first non-peptide pill, is ~11% but can be taken anytime. Both trade some efficacy for the absence of an injection.
Are these the same as the research peptides sold online? Semaglutide, tirzepatide, retatrutide and cagrilintide are sold for laboratory research use only and are not approved for human use in that form. The branded medicines (Wegovy, Zepbound, Foundayo) are prescription pharmaceuticals. This article discusses the published clinical evidence, not a protocol for personal use.
Why can’t I just compare the weight-loss percentages directly? Because they come from different trials with different patient populations and different statistical estimands. Only head-to-head trials (like SURMOUNT-5) give a true comparison; everything else is an approximate inference.
References
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. NCT05822830.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972.
- Eli Lilly and Company. Lilly’s triple agonist retatrutide delivered powerful weight loss in TRIUMPH-1 (Phase 3 topline). May 21, 2026. Trial design: Giblin JP, et al. Diabetes Obes Metab. 2026. doi:10.1111/dom.70209.
- Garvey WT, Blüher M, Davies MJ, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). N Engl J Med. 2025. doi:10.1056/NEJMoa2502081.
- Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg once per day in adults with overweight or obesity (OASIS 1). Lancet. 2023;402(10403):705-719. doi:10.1016/S0140-6736(23)01185-6.
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025;393(19):1796-1806. doi:10.1056/NEJMoa2511774.
Research and educational use only. This article summarizes published clinical research and is not medical advice, a treatment recommendation, or a substitute for a licensed clinician. Weight-loss figures are drawn from manufacturer-funded trials and, except where a head-to-head trial is named, cross-trial comparisons are approximate and not equivalent. Semaglutide, tirzepatide, retatrutide and cagrilintide referenced here are sold for laboratory research purposes only and are not intended to diagnose, treat, cure, or prevent any disease; orforglipron (Foundayo) is a prescription medication included for comparison only.